In summary, we have demonstrated that TRT can up-regulate PD-L1 expression, and that TRT combined with anti-PD-L1 mAb can stimulate CD8+ T cell infiltration, altering the tumor microenvironment and resulting in a synergistic anti-tumor immunity in MC38 colon carcinoma model. This evidence concerns the gene CD8A and colon carcinoma.